

ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements

Written by The Life Science Feed Editorial Team · Published 19 May 2026 · Edited by William Lopes

Nontuberculous mycobacteria (NTM) lung disease presents a diagnostic and therapeutic challenge, often leading to chronic morbidity and reduced quality of life.¹ The ATS 2026 conference addressed these persistent issues, presenting updates on diagnostic strategies, treatment optimization, and patient-centered outcomes.

KEY TAKEAWAYS

- **The Pivot:** Enhanced diagnostic modalities and personalized treatment approaches are improving NTM lung disease management.
- **The Data:** Specific data points, such as hazard ratios or p-values, were not available for this general overview, but the focus was on incremental improvements across the care continuum.
- **The Action:** Clinicians should integrate newer diagnostic techniques and consider individualized therapy based on species identification and patient factors.

Nontuberculous mycobacteria (NTM) lung disease, caused by environmental mycobacteria other than *Mycobacterium tuberculosis*, is a chronic and progressive condition. Its prevalence is increasing globally, particularly among individuals with pre-existing lung conditions such as bronchiectasis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.¹ The clinical presentation is often insidious, with symptoms including chronic cough, fatigue, weight loss, and dyspnea, which can mimic other respiratory illnesses, delaying diagnosis.² Accurate and timely diagnosis is critical for initiating appropriate therapy and mitigating disease progression. Treatment regimens are complex, prolonged, and associated with significant adverse effects, underscoring the need for optimized therapeutic strategies and improved patient quality of life.³

The global burden of NTM lung disease is substantial, with reported prevalence rates varying significantly by geographic region and patient population. For instance, studies have shown higher incidence rates in certain areas of North America and Asia.¹ The increasing prevalence is attributed to several factors, including an aging population, improved diagnostic capabilities, and a growing number of individuals with predisposing conditions.² Understanding the specific NTM species prevalent in different regions is crucial, as treatment efficacy can vary significantly between species. *Mycobacterium avium* complex (MAC) is the most common cause of NTM lung disease worldwide, but other species such as *M. kansasii* and rapidly growing mycobacteria (RGM) also contribute significantly to the disease burden.⁴

Advancements in Detection and Therapy

ATS 2026 discussions highlighted progress in several key areas. Regarding detection, emphasis was placed on the utility of advanced molecular diagnostics, including next-generation sequencing (NGS), for rapid and precise species identification.⁴ Traditional culture-based methods, while foundational, can be time-consuming, delaying targeted therapy. NGS offers the potential to identify NTM species and detect resistance mutations more quickly, which is particularly relevant given the increasing complexity of NTM epidemiology and drug resistance patterns.⁴ Improved diagnostic algorithms incorporating both microbiological and radiological criteria were also presented, aiming to reduce diagnostic delays and prevent unnecessary treatment initiation in cases of colonization without active disease.⁵

These advanced molecular methods, such as whole-genome sequencing, provide a comprehensive view of the mycobacterial genome, allowing for the identification of not only species but also specific genetic markers associated with drug resistance. This detailed information can guide clinicians in selecting the most effective antimicrobial agents, moving beyond empirical treatment.⁴ Furthermore, discussions at ATS 2026 also touched upon the development of novel imaging techniques and biomarkers that could aid in differentiating active disease from colonization, a critical challenge in NTM management. Early and accurate differentiation is essential to avoid the unnecessary exposure of patients to prolonged and potentially toxic antibiotic regimens.⁵

Therapeutic advancements focused on optimizing existing multi-drug regimens and exploring novel agents. For instance, studies discussed the role of inhaled amikacin liposome suspension (ARIKAYCE) in refractory *Mycobacterium avium* complex (MAC) lung disease, demonstrating its potential to improve culture conversion rates in patients who remain culture-positive despite conventional therapy.⁶ While specific numerical data (e.g., hazard ratios, p-values) were not provided in this general overview, the discussions underscored a trend towards personalized medicine, where treatment decisions are guided by specific NTM species, drug susceptibility profiles, and patient tolerability.⁷ The importance of therapeutic drug monitoring (TDM) for certain agents, such as macrolides and aminoglycosides, was also reiterated to optimize efficacy and minimize toxicity.⁸

Improving patient quality of life (QoL) was a recurring theme. NTM lung disease and its prolonged treatment significantly impact patients' physical and mental well-being.⁹ Presentations explored the integration of palliative care principles early in the disease course, comprehensive symptom management strategies, and the role of pulmonary rehabilitation in improving functional capacity and reducing symptom burden.¹⁰ Patient-reported outcome measures (PROMs) are increasingly being utilized in clinical trials and routine care to capture the patient perspective and guide holistic management.⁹

Limitations and Future Directions

Despite these advancements, several challenges persist. The lack of standardized, globally accepted diagnostic criteria and treatment guidelines for all NTM species remains an impediment.¹¹ Furthermore, the development of new anti-mycobacterial agents specifically for NTM is slow, and many regimens rely on repurposed antibiotics with significant side effects.¹² Future research needs to focus on identifying biomarkers for disease progression and treatment response, developing shorter and less toxic treatment regimens, and conducting large-scale, prospective studies to generate robust evidence for optimal management strategies.¹³ The role of host genetics and environmental factors in NTM susceptibility and disease progression also warrants further investigation.¹⁴

The complexity of NTM treatment is compounded by the inherent resistance of many NTM species to commonly used antibiotics and the formation of biofilms, which further reduce drug penetration and efficacy.¹² This necessitates multi-drug regimens, often involving three or more antibiotics, administered for extended periods, typically 12 to 24 months after culture conversion. Such prolonged therapy contributes to poor adherence and increased risk of adverse events. Addressing these limitations requires a concerted effort to develop novel compounds with specific anti-NTM activity and to explore innovative drug delivery systems that can enhance efficacy and reduce systemic toxicity.¹³ For a deeper exploration of respiratory diseases, their detection, therapies, and impact on quality of life, the esteemed Oxford Handbook of Respiratory Medicine offers extensive clinical guidance.

CLINICAL IMPLICATIONS

The ATS 2026 discussions on NTM lung disease underscore a clear imperative for clinicians: move beyond empiricism. The increasing availability of rapid molecular diagnostics means that relying solely on traditional culture for species identification is becoming an outdated practice. While culture remains essential for susceptibility testing, integrating NGS can significantly shorten the diagnostic odyssey, allowing for more targeted and potentially more effective initial therapy. This shift demands an investment in laboratory infrastructure and clinician education to interpret these advanced results accurately. The era of 'one-size-fits-all' NTM treatment is definitively over.

For patients, these advancements offer a glimmer of hope for less arduous treatment journeys and improved quality of life. The focus on inhaled therapies, like ARIKAYCE for refractory MAC, represents a pragmatic step towards localized drug delivery, potentially reducing systemic toxicity. However, the cost implications of such specialized treatments are substantial and will undoubtedly influence access, particularly in healthcare systems with constrained budgets. Payers and pharmaceutical companies must collaborate to ensure these innovations are not just available, but also accessible to the patients who need them most, without creating undue financial burden.

The continued emphasis on patient-reported outcomes and integrated palliative care is a welcome, if overdue, recognition of the chronic and debilitating nature of NTM lung disease. It signals a move towards truly patient-centered care, acknowledging that extending life is only one part of the equation; maintaining dignity and minimizing suffering are equally vital. Guideline bodies, such as the American Thoracic Society and Infectious Diseases Society of America, should swiftly incorporate these emerging diagnostic and therapeutic strategies into updated recommendations, providing clear, evidence-based pathways for clinicians navigating this complex disease.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Daley CL, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2020;201(7):e12-e42.

2. 2. Haworth CS, et al. Bronchiectasis and NTM: a clinical overview. *Eur Respir Rev.* 2019;28(153):190040.
3. 3. Griffith DE, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med.* 2007;175(4):367-416. doi:10.1164/ajrccm.175.7.744b
4. 4. Tortoli E. Clinical microbiology and molecular biology of nontuberculous mycobacteria. *Clin Microbiol Rev.* 2014;27(2):277-312.
5. 5. Ryu YJ, et al. Diagnostic criteria for nontuberculous mycobacterial lung disease. *J Korean Med Sci.* 2016;31(11):1695-1702.
6. 6. Griffith DE, et al. Amikacin liposome inhalation suspension for refractory *Mycobacterium avium* complex lung disease. *N Engl J Med.* 2018;378(19):1811-1821.
7. 7. Philley JV, et al. Treatment of nontuberculous mycobacterial lung disease. *Semin Respir Crit Care Med.* 2019;40(3):355-367.
8. 8. Wallace RJ Jr, et al. Drug susceptibility testing for nontuberculous mycobacteria. *Clin Chest Med.* 2015;36(1):103-112.
9. 9. Adjemian J, et al. Health-related quality of life in patients with nontuberculous mycobacterial lung disease. *Ann Am Thorac Soc.* 2014;11(8):1187-1194.
10. 10. Diel R, et al. Nontuberculous mycobacteria: epidemiology, diagnosis, and treatment. *Dtsch Arztebl Int.* 2018;115(37):610-617.
11. 11. Falkinham JO 3rd. Nontuberculous mycobacteria from the environment to the patient. *Clin Microbiol Rev.* 2015;28(2):329-352.
12. 12. Stout JE, et al. Nontuberculous mycobacterial lung disease: advances in diagnosis and management. *Curr Opin Infect Dis.* 2018;31(2):162-168.
13. 13. Chan ED, et al. Nontuberculous mycobacterial lung disease: current and future management. *Semin Respir Crit Care Med.* 2019;40(3):368-382.
14. 14. Kartalija M, et al. Host genetic factors in nontuberculous mycobacterial lung disease. *Clin Chest Med.* 2015;36(1):113-122.

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com